Leaderboards/Lymphoma Diagnosis and Treatment

Lymphoma Diagnosis and Treatment

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Papers

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127

Science|2024

148 cit.

Publication in The Lancet (2024) [114 citations, W4400268343]

The Lancet|2024

114 cit.

Publication in Nature Communications (2024) [87 citations, W4393040331]

Nature Communications|2024

87 cit.

Publication in Frontiers in Immunology (2024) [79 citations, W4391608860]

Frontiers in Immunology|2024

79 cit.

An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma

Nature Medicine|2025

42 cit.

Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials—a LYSA and GLA/ DSHNHL collaboration

Leukemia|2024

12 cit.

Genetic subtype-guided immunochemotherapy in relapsed and refractory diffuse large B cell lymphoma: a phase 2 investigator-initiated nonrandomized clinical trial (GUIDANCE-06)

Signal Transduction and Targeted Therapy|2025

7 cit.

The development process of ‘fit-for-purpose’ imaging biomarkers to characterize the tumor microenvironment

Frontiers in Medicine|2024

5 cit.

Publication in Transplantation and Cellular Therapy (2025) [1 citation, W4407977349]

Transplantation and Cellular Therapy|2025

1 cit.

Risk prediction in diffuse large B-cell lymphoma improves when combining baseline PET features with interim PET response

Haematologica|2025

1 cit.

Emerging Leaders

Drafting the new consensus

Papers

Impact of etoposide and ASCT on survival among patients aged &lt;65 years with stage II to IV PTCL: a population-based cohort study

Blood|2022

70 cit.

<scp>R‐miniCHOP</scp> versus <scp>R‐CHOP</scp> in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study

American Journal of Hematology|2023

31 cit.

Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy

Haematologica|2023

30 cit.

Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As High Risk By Circulating Tumor DNA (ctDNA) Dynamics: Preliminary Safety and Efficacy Results

Blood|2023

20 cit.

Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC

Journal for ImmunoTherapy of Cancer|2022

19 cit.

Efficacy of Laser in Hair Removal: A Network Meta-analysis

Journal of Cosmetic and Laser Therapy|2023

19 cit.

Quantitative PCR–Based Method to Assess Cell-Free DNA Quality, Adjust Input Mass, and Improve Next-Generation Sequencing Assay Performance

Journal of Molecular Diagnostics|2022

14 cit.

Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis

European Journal of Cancer|2022

13 cit.

Low Mutational Burden of Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in Patients with Primary Sjogren’s Syndrome

Cancers|2022

12 cit.

A population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics

Blood Cancer Journal|2023

12 cit.

Current Senior Leaders

Wrote the book, still writing it

Papers

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

Nature|2000

10k cit.

A microRNA expression signature of human solid tumors defines cancer gene targets

Proceedings of the National Academy of Sciences|2006

5.7k cit.

CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

New England Journal of Medicine|2002

5.6k cit.

Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia

Proceedings of the National Academy of Sciences|2002

5k cit.

Revised Response Criteria for Malignant Lymphoma

Journal of Clinical Oncology|2007

4.4k cit.

Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers

Proceedings of the National Academy of Sciences|2004

4.1k cit.

MicroRNA Gene Expression Deregulation in Human Breast Cancer

Cancer Research|2005

4.1k cit.

The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma

New England Journal of Medicine|2002

3.9k cit.

miR-15 and miR-16 induce apoptosis by targeting BCL2

Proceedings of the National Academy of Sciences|2005

3.5k cit.

A predictive model for aggressive non-Hodgkin's lymphoma

Unknown Journal|1993

3.5k cit.

Reagents for Lymphoma Diagnosis and Treatment

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 66

Rab1A (D3X9S) Rabbit Monoclonal Antibody

Cited in 12 papers

#13075$161,351

View Evidence →

Leica BiosystemsEvidence 72

Anti-CD19 Monoclonal Antibody, Unconjugated

CD79______??,

🌟 All-Time

Most validated

Innovative ResearchEvidence 72

Mouse Anti-Human CD1a Monoclonal Antibody, Alexa Fluor 488 Conjugated, Clone 143

Mutated melanoma-associated antigen 1

Epstein Barr Virus Latent membrane Protein

Cited in 13 papers

#M0897

View Evidence →

Lymphoma Diagnosis and Treatment

Rising Stars

Researchers

Papers

Emerging Leaders

Researchers

Papers

Current Senior Leaders

Researchers

Papers

Reagents for Lymphoma Diagnosis and Treatment

🔥 Trending

⭐ Top Rated

🌟 All-Time